A high-dimensional cytometry atlas of peripheral blood over the human life span
- Jalali, Sedigheh, Harpur, Christopher, Piers, Adam, Auladell, Maria, Perriman, Louis, Li, Shuo, An, Kim, Anderson, Jeremy, Berzins, Stuart, Licciardi, Paul, Ashhurst, Thomas, Konstantinov, Igor, Pellicci, Daniel
- Authors: Jalali, Sedigheh , Harpur, Christopher , Piers, Adam , Auladell, Maria , Perriman, Louis , Li, Shuo , An, Kim , Anderson, Jeremy , Berzins, Stuart , Licciardi, Paul , Ashhurst, Thomas , Konstantinov, Igor , Pellicci, Daniel
- Date: 2022
- Type: Text , Journal article
- Relation: Immunology and Cell Biology Vol. 100, no. 10 (2022), p. 805-821
- Full Text:
- Reviewed:
- Description: Age can profoundly affect susceptibility to a broad range of human diseases. Children are more susceptible to some infectious diseases such as diphtheria and pertussis, while in others, such as coronavirus disease 2019 and hepatitis A, they are more protected compared with adults. One explanation is that the composition of the immune system is a major contributing factor to disease susceptibility and severity. While most studies of the human immune system have focused on adults, how the immune system changes after birth remains poorly understood. Here, using high-dimensional spectral flow cytometry and computational methods for data integration, we analyzed more than 50 populations of immune cells in the peripheral blood, generating an immune cell atlas that defines the healthy human immune system from birth up to 75 years of age. We focused our efforts on children under 18 years old, revealing major changes in immune cell populations after birth and in children of schooling age. Specifically, CD4+ T effector memory cells, V
- Authors: Jalali, Sedigheh , Harpur, Christopher , Piers, Adam , Auladell, Maria , Perriman, Louis , Li, Shuo , An, Kim , Anderson, Jeremy , Berzins, Stuart , Licciardi, Paul , Ashhurst, Thomas , Konstantinov, Igor , Pellicci, Daniel
- Date: 2022
- Type: Text , Journal article
- Relation: Immunology and Cell Biology Vol. 100, no. 10 (2022), p. 805-821
- Full Text:
- Reviewed:
- Description: Age can profoundly affect susceptibility to a broad range of human diseases. Children are more susceptible to some infectious diseases such as diphtheria and pertussis, while in others, such as coronavirus disease 2019 and hepatitis A, they are more protected compared with adults. One explanation is that the composition of the immune system is a major contributing factor to disease susceptibility and severity. While most studies of the human immune system have focused on adults, how the immune system changes after birth remains poorly understood. Here, using high-dimensional spectral flow cytometry and computational methods for data integration, we analyzed more than 50 populations of immune cells in the peripheral blood, generating an immune cell atlas that defines the healthy human immune system from birth up to 75 years of age. We focused our efforts on children under 18 years old, revealing major changes in immune cell populations after birth and in children of schooling age. Specifically, CD4+ T effector memory cells, V
A three-stage developmental pathway for human V
- Perriman, Louis, Tavakolinia, Naeimeh, Jalali, Sedigheh, Li, Shuo, Hickey, Peter, Amann-Zalcenstein, Daniela, Ho, William, Baldwin, Tracey, Piers, Adam, Konstantinov, Igor, Anderson, Jeremy, Stanley, Edouard, Licciardi, Paul, Kannourakis, George, Naik, Shalin, Koay, Hui-Fern, Mackay, Laura, Berzins, Stuart, Pellicci, Daniel
- Authors: Perriman, Louis , Tavakolinia, Naeimeh , Jalali, Sedigheh , Li, Shuo , Hickey, Peter , Amann-Zalcenstein, Daniela , Ho, William , Baldwin, Tracey , Piers, Adam , Konstantinov, Igor , Anderson, Jeremy , Stanley, Edouard , Licciardi, Paul , Kannourakis, George , Naik, Shalin , Koay, Hui-Fern , Mackay, Laura , Berzins, Stuart , Pellicci, Daniel
- Date: 2023
- Type: Text , Journal article
- Relation: Science Immunology Vol. 8, no. 85 (2023), p.
- Full Text: false
- Reviewed:
- Description: V
Aerosol delivery of palivizumab in a neonatal lamb model of respiratory syncytial virus infection
- Edirisinghe, Hasindu, Rajapaksa, Anushi, Royce, Simon, Sourial, Magdy, Bischof, Robert, Anderson, Jeremy, Sarila, Gulcan, Nguyen, Cattram, Mulholland, Kim, Do, Lien, Licciardi, Paul
- Authors: Edirisinghe, Hasindu , Rajapaksa, Anushi , Royce, Simon , Sourial, Magdy , Bischof, Robert , Anderson, Jeremy , Sarila, Gulcan , Nguyen, Cattram , Mulholland, Kim , Do, Lien , Licciardi, Paul
- Date: 2023
- Type: Text , Journal article
- Relation: Viruses Vol. 15, no. 11 (2023), p.
- Full Text:
- Reviewed:
- Description: (1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been limited mostly to high-income countries. Following our previous study showing the successful lung deposition of aerosolised palivizumab in lambs, this current study evaluated the “proof-of-principle” effect of aerosolised palivizumab delivered as a therapeutic to neonatal lambs following RSV infection. (2) Methods: Neonatal lambs were intranasally inoculated with RSV-A2 on day 0 (day 3 post-birth) and treated with aerosolised palivizumab 3 days later (day 3 post-inoculation). Clinical symptoms, RSV viral load and inflammatory response were measured post-inoculation. (3) Results: Aerosolised therapeutic delivery of palivizumab did not reduce RSV viral loads in the nasopharynx nor the bronchoalveolar lavage fluid, but resulted in a modest reduction in inflammatory response at day 6 post-inoculation compared with untreated lambs. (4) Conclusions: This proof-of-principle study shows some evidence of aerosolised palivizumab reducing RSV inflammation, but further studies using optimized protocols are needed in order to validate these findings. © 2023 by the authors.
- Authors: Edirisinghe, Hasindu , Rajapaksa, Anushi , Royce, Simon , Sourial, Magdy , Bischof, Robert , Anderson, Jeremy , Sarila, Gulcan , Nguyen, Cattram , Mulholland, Kim , Do, Lien , Licciardi, Paul
- Date: 2023
- Type: Text , Journal article
- Relation: Viruses Vol. 15, no. 11 (2023), p.
- Full Text:
- Reviewed:
- Description: (1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been limited mostly to high-income countries. Following our previous study showing the successful lung deposition of aerosolised palivizumab in lambs, this current study evaluated the “proof-of-principle” effect of aerosolised palivizumab delivered as a therapeutic to neonatal lambs following RSV infection. (2) Methods: Neonatal lambs were intranasally inoculated with RSV-A2 on day 0 (day 3 post-birth) and treated with aerosolised palivizumab 3 days later (day 3 post-inoculation). Clinical symptoms, RSV viral load and inflammatory response were measured post-inoculation. (3) Results: Aerosolised therapeutic delivery of palivizumab did not reduce RSV viral loads in the nasopharynx nor the bronchoalveolar lavage fluid, but resulted in a modest reduction in inflammatory response at day 6 post-inoculation compared with untreated lambs. (4) Conclusions: This proof-of-principle study shows some evidence of aerosolised palivizumab reducing RSV inflammation, but further studies using optimized protocols are needed in order to validate these findings. © 2023 by the authors.
- «
- ‹
- 1
- ›
- »